Results 21 to 30 of about 165,040 (305)

Bacteriocin Production in Vancomycin-Resistant and Vancomycin-Susceptible Enterococcus Isolates of Different Origins [PDF]

, 2001
Bacteriocin production was determined for 218 Enterococcus isolates (Enterococcus faecalis [93] and E. faecium [125]) obtained from different origins (human clinical samples [87], human fecal samples [78], sewage [28], and chicken samples [25]) and ...
Jiménez Díaz, Rufino, Torres, Carmen, Rubio, Carmen, Rafael Gómez-Lus, Gómez-Lus, R., Baquero, F., Tenorio, Carmen, Carmen Torres, Carmen Rubio, Baquero, Fernando, Tenorio, C. [0000-0002-8099-1208], Rubio, C., Carmen Tenorio, Rufino Jiménez-Dı́az, Gómez-Lus, Rafael, Torres, C. [0000-0003-3709-1690], Fernando Baquero, Jiménez-Díaz, R. [0000-0001-7881-511X], Campo, Rosa del, Rosa Del Campo, Del Campo, R. [0000-0003-1147-7923]   +20 more
core   +1 more source

Acute Kidney Injury in Pediatric Treated with Vancomycin and Piperacillin-Tazobactam in Tertiary Care Hospital

International Journal of Pediatrics, 2018
Background. Vancomycin and piperacillin-tazobactam (PTZ) are commonly used as empirical therapy for patients with health care associated infections. Vancomycin has been recognized as a nephrotoxic agent and in a few cases in the literature PTZ has been ...
Mohammed Al Nuhait, Laila C. Abu Esba, Khalid Al Harbi, Meshary Al Meshary, Rami T. Bustami   +4 more
doaj   +1 more source

Risk of vancomycin-resistant enterococci bloodstream infection among patients colonized with vancomycin-resistant enterococci

Brazilian Journal of Infectious Diseases, 2015
Background: Vancomycin-resistant enterococci colonization has been reported to increase the risk of developing infections, including bloodstream infections.
Ahu Kara, İlker Devrim, Nuri Bayram, Nagehan Katipoğlu, Ezgi Kıran, Yeliz Oruç, Nevbahar Demiray, Hurşit Apa, Gamze Gülfidan   +8 more
doaj   +1 more source

Vancomycin Therapeutic Drug Monitoring (TDM) and Its Association with Clinical Outcomes: A Retrospective Cohort

Journal of Infection and Public Health, 2022
Background: Therapeutic drug monitoring (TDM) has proven effectiveness in maintaining efficacy and reducing toxicities associated with vancomycin. A trough level of (15–20 mg/L) for MRSA serious infections is recommended.
Juhaina Salim Al-Maqbali, Zahra Al Shukri, Nawf Al Sabahi, Intisar AL-Riyami, Abdullah M. Al Alawi   +4 more
doaj   +1 more source

Risk factors for vancomycin treatment failure in heterogeneous vancomycin-intermediate Staphylococcus aureus bacteremia

Microbiology Spectrum
The incidence of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) infection is increasing and is associated with vancomycin treatment failures.
Ji Hyun Yun, Euijin Chang, Seongman Bae, Jiwon Jung, Min Jae Kim, Yong Pil Chong, Sung-Han Kim, Sang-Ho Choi, Sang-Oh Lee, Yang Soo Kim   +9 more
doaj   +1 more source

An Unusual Case of Ototoxicity with Use of Oral Vancomycin

Case Reports in Infectious Diseases, 2018
Introduction. Systemic absorption of oral vancomycin is poor due to the size of the molecule and its pharmacokinetics. It has an elimination half life of 5–11 hours in patients with normal renal function.
Umut Gomceli, Srija Vangala, Cosmina Zeana, Paul J. Kelly, Manisha Singh   +4 more
doaj   +1 more source

Parenterally administered vancomycin in 29 dogs and 7 cats (2003‐2017)

Journal of Veterinary Internal Medicine, 2019
Background Vancomycin is commonly used to treat resistant bacterial infections in people. Reported adverse effects of vancomycin in people include acute kidney injury (AKI), neutropenia, and systemic allergic reaction.
Ian M. DeStefano, Annie S. Wayne, Elizabeth A. Rozanski, Jonathan M. Babyak   +3 more
doaj   +1 more source

Vancomycin

Medical Clinics of North America, 1995
Vancomycin is a nontoxic glycopeptide antibiotic most often used to treat serious gram-positive infections, C. difficile diarrhea/colitis, and endocarditis and hemodialysis shunt prophylaxis. Vancomycin should not be added to drug regimens for gram-positive coverage, and the empiric use of vancomycin should be discouraged to avoid the emergence of VRE.
openaire   +2 more sources

Risk factors for vancomycin resistance in patients with Enterococcus faecium bloodstream infections: an analysis of the Munich Multicentric Enterococci Cohort

Microbiology Spectrum
Enterococcus faecium is difficult to treat owing to its intrinsic and acquired resistance to antibiotics, particularly vancomycin. Vancomycin-resistant Enterococcus faecium is an important cause of bloodstream infections in healthcare settings with ...
Laura Wagner, Milena Wurst, Johanna Erber, Tobias Bachfischer, Bernhard Haller, Sabine Gleich, Karl Dichtl, Roland M. Schmid, Julian Triebelhorn, Florian Voit, Ulrich Seybold, Dirk H. Busch, Patrick C. Rämer, Christoph D. Spinner, Jochen Schneider, Kathrin Rothe   +15 more
doaj   +1 more source

Iterative Chemical Engineering of Vancomycin Leads to Novel Vancomycin Analogs With a High in Vitro Therapeutic Index

Frontiers in Microbiology, 2018
Vancomycin is a glycopeptide antibiotic that inhibits transpeptidation during cell wall synthesis by binding to the D-Ala-D-Ala termini of lipid II. For long, it has been used as a last resort antibiotic.
Nigam M. Mishra, Izabela Stolarzewicz, Izabela Stolarzewicz, David Cannaerts, Joris Schuermans, Rob Lavigne, Yannick Looz, Bart Landuyt, Liliane Schoofs, Dominique Schols, Jan Paeshuyse, Peter Hickenbotham, Martha Clokie, Walter Luyten, Walter Luyten, Erik V. Van der Eycken, Erik V. Van der Eycken, Yves Briers, Yves Briers   +18 more
doaj   +1 more source